Latest breakthroughs in cancer research, treatment, and prevention
643 articles
A phase 2 trial shows rogaratinib produces durable responses in a hard-to-treat GIST subtype driven by epigenetic oncogene activation.
Phase 2 trial explores whether combining oncolytic virus therapy with immunotherapy can rescue patients whose melanoma progressed on PD-1 blockade.
A phase I/II trial tests SV-BR-1-GM, a whole-cell cancer vaccine, combined with the checkpoint inhibitor retifanlimab in patients with metastatic breast cancer.
Circulating tumor DNA testing alongside primary treatment may sharpen prognosis for men with metastatic prostate cancer.
CRC cells exploit a heme-SDH-CoQ axis to neutralize iron-induced oxidative stress, revealing new therapeutic targets.
A pilot trial tested a comprehensive physical, mental, and spiritual intervention for cancer survivors, tracking outcomes at 6 months post-program.
Nivolumab plus standard chemotherapy receives FDA approval for classical Hodgkin lymphoma, expanding immunotherapy's role in blood cancers.
MSK-led research drove 10 FDA cancer drug approvals in 2025, including nivolumab combined with chemotherapy for classical Hodgkin lymphoma.
Nivolumab added to standard chemotherapy wins FDA approval, offering a new frontline option for classical Hodgkin lymphoma patients.
A phase trial finds paricalcitol safely remodels the tumor microenvironment in metastatic pancreatic cancer, boosting immune cell infiltration.
McGill scientists boosted NK cell cancer-killing power using reversible drug treatment, targeting leukemia, glioblastoma, and triple-negative breast cancer.
A landmark study of 500 cat tumors reveals shared cancer-driving mutations with humans, pointing toward new breast cancer treatments.
